Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marme F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching P, Lux MP, Lueftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 14
DOI: 10.1016/j.jbo.2018.09.010
Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study.
APA:
Hadji, P., Stoetzer, O., Decker, T., Kurbacher, C.M., Marme, F., Schneeweiss, A.,... Tesch, H. (2019). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of Bone Oncology, 14. https://doi.org/10.1016/j.jbo.2018.09.010
MLA:
Hadji, Peyman, et al. "The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial." Journal of Bone Oncology 14 (2019).
BibTeX: Download